Whole blood pretreatment device and use method thereof

The fully automated system, utilizing a three-layer filter membrane structure and pneumatic filtration technology, solves the problems of complexity in whole blood processing and accuracy in existing technologies, achieving the effects of simplified operation and improved testing accuracy.

CN118961353APending Publication Date: 2024-11-15HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411122456.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing chemiluminescence detection technologies require whole blood processing using equipment such as centrifuges, which is complex, expensive, and may damage blood components, affecting detection accuracy.

Method used

The system employs a fully automated system including a filtration device, reaction vessel, and pressure pump. It utilizes a three-layer filter membrane structure and air pressure filtration technology to avoid centrifugation, simplifying operation and improving detection accuracy.

Benefits of technology

It reduces equipment costs and operational complexity, avoids damage to blood components, improves plasma extraction volume and the accuracy of test results, and simplifies the whole blood processing process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961353A_ABST
    Figure CN118961353A_ABST
Patent Text Reader

Abstract

The invention provides a whole blood pretreatment device and a using method thereof.The device comprises a filtering device, a reaction cup and a pressure pump and is used in cooperation with a full-automatic light-emitting instrument, and the filtering device structurally comprises a blood filtering film, glass fibers and a blood filtering film from top to bottom. According to the kit, the whole blood filtering device and the reaction cup are integrated, air pressure filtering is utilized, chemiluminescence detection is carried out, equipment such as a centrifugal machine is not needed in the whole blood treatment process, damage to some components in blood in the centrifugal treatment process is avoided, the accuracy of a detection result is improved, and the complexity of whole blood treatment is simplified. The whole blood treatment and detection process is carried out in the closed reaction cup set, so that the pollution of the external environment to the blood sample is avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedical detection, and in particular relates to a whole blood pretreatment device and a use method thereof. Background Art

[0002] Chemiluminescence detection is a commonly used biomedical detection method, widely used in clinical diagnosis, drug screening, environmental monitoring and other fields. This method usually requires the use of serum or plasma as the test sample, because blood cells and other components in whole blood may interfere with the signal value and affect the accuracy of the test results. Therefore, before performing chemiluminescence detection, blood or body fluids need to be pre-processed to remove unnecessary interfering substances.

[0003] In traditional laboratory analysis methods, the most common way to separate plasma is to centrifuge whole blood to precipitate blood cells (red blood cells, white blood cells) and other components in the blood (platelets, plasma albumin, globulin, etc.), and obtain supernatant (plasma), and then use the obtained plasma for chemiluminescence detection. This process usually requires the use of equipment such as centrifuges, but in order to achieve the ideal separation effect, a large amount of blood samples, dedicated centrifuges and power supply equipment, and professional operators are usually required. In addition, centrifugal equipment is large and complex to operate, and requires high technical operation. The upper plasma / serum obtained by centrifugation is very easy to remix during the transfer process, resulting in a small amount of extraction and inaccurate test results.

[0004] Patent document CN110857904A discloses a method for obtaining plasma from a whole blood sample, a blood filter and a microfluidic chip, wherein the blood filter comprises a coarse filtration module and a purification module, wherein the coarse filtration module comprises a first filter cup and a filter element, wherein the filter element is preferably an acetate fiber column, and the purification module comprises a second filter cup, an annular pressing sheet and a filter membrane, wherein the filter membrane is a Pall Vivid GR plasma separation membrane. The filtration speed of this method is slow, and when the filter membrane has too many layers or is overloaded and blocked, it is difficult to filter out the plasma, resulting in low plasma recovery efficiency.

[0005] Patent document CN117180991A discloses a combined filter for separating plasma from whole blood, including a whole blood sample loading chamber, a first combined filter membrane, an intermediate chamber, a second combined filter membrane and a plasma collection chamber arranged in sequence along the flow filtration direction of the whole blood sample, and the whole blood sample is filtered multiple times by the first combined filter membrane and the second combined filter membrane to obtain a plasma sample. The combined filter membrane structure and processing method used in this method are cumbersome, and an additional vacuum generating device is required to set different negative pressure values ​​according to the whole blood sample filtration process, and the negative pressure inside the vacuum container is controlled by closed-loop feedback, which is complicated to operate.

[0006] Although existing blood processing technology can obtain relatively pure plasma, the entire processing process is relatively complicated and requires the use of equipment such as centrifuges, which not only increases the cost of the equipment, but also increases the complexity of the operation. In addition, the centrifugal process may damage certain components in the blood, affecting the accuracy of the test results. Therefore, how to simply, quickly and effectively process whole blood without using a centrifuge, so that the luminescent detection instrument integrates whole blood sampling, whole blood processing, plasma sampling and detection, is an important issue facing current chemiluminescent detection technology. Summary of the invention

[0007] In view of the problems existing in the prior art, the present invention provides a device including a filter device, a reaction cup and a pressure pump, which is used in conjunction with a fully automated luminescence instrument, wherein the structure of the filter device from top to bottom is a blood filter membrane, glass fiber, and a blood filter membrane. The set integrates the whole blood filter device with the reaction cup, utilizes air pressure filtration, and performs chemiluminescence detection. The entire blood processing process does not require the use of equipment such as a centrifuge, thereby avoiding the destruction of certain components in the blood during the centrifugal processing process, improving the accuracy of the test results, and simplifying the complexity of whole blood processing. The entire blood processing and detection process is carried out in a closed reaction cup set, avoiding the contamination of the blood sample by the external environment.

[0008] On the one hand, the present invention provides a whole blood pretreatment device, which includes a package structure composed of a filter device and a reaction cup. The filter device is composed of a layer of blood filter membrane, a layer of glass fiber, and a layer of blood filter membrane from top to bottom.

[0009] The whole blood pretreatment device provided by the present invention includes a whole blood filtering device and a reaction cup. The reaction cup set should be designed to withstand a certain pressure so as to perform pressurized treatment. The filtering device should be designed to effectively filter the whole blood, retain the plasma, and avoid damaging the components in the plasma. The whole blood filtering device is placed above the reaction cup so that the whole blood can be preliminarily filtered before being added to the reaction cup to remove unnecessary interfering substances. This design avoids the step of using a centrifuge or other equipment for centrifugal treatment in the traditional method, reduces equipment costs, and saves time and effort.

[0010] Furthermore, the device also includes a pressure pump, which applies pressure to the filtering device.

[0011] In the traditional centrifugal separation method, centrifugal force is mainly used to separate plasma from other components, and then the upper plasma is drawn. In this process, plasma and blood cells are easily remixed, resulting in a small amount of extraction and inaccurate test results. The device is used in conjunction with a pressure pump, without the need for the centrifugal treatment step in the traditional method, reducing the complexity of blood processing and equipment costs. At the same time, the pressure pump provides appropriate pressure, so that whole blood is separated under pressure in the filtration device to obtain plasma, which increases the plasma extraction content and improves the accuracy of subsequent test results.

[0012] In some embodiments, a soft plug ring is installed at the outlet of the conduit connected to the pressure pump to enhance the sealing performance when the pipe mouth contacts the filter device, and the pressure can be adjusted and set by adjusting the control valve of the pressure pump.

[0013] Furthermore, the first layer and the third layer of the device have the same material and thickness, and the aperture of the second layer is larger than that of the first layer.

[0014] In some methods, the first and third layers use the same thickness and material of the filter membrane, and the pore size is smaller than the first layer. The first layer of blood filter membrane can effectively intercept most red blood cells, white blood cells and platelets; the second layer of glass fiber material is fluffier than the blood filter membrane, giving red blood cells a buffer and increasing the distance of liquid movement. In addition, the glass fiber is treated with anti-RBC solution to continue to efficiently intercept red blood cells. The third layer can intercept the remaining red blood cells, white blood cells and platelets. The three-layer filter membrane stack increases the volume of whole blood that can be filtered, and the second layer of glass fiber material also prevents red blood cells from rupturing during pressurization.

[0015] In some embodiments, in the device, the first layer of blood filter membrane has a thickness of 0.2 to 0.5 mm, a pore size of 3 to 15 μm, and is made of a single-layer matrix membrane; the second layer of glass fiber has a thickness of 0.1 to 0.8 mm, a pore size of 0.1 to 0.3 mm, and is made of glass fiber; the third layer of blood filter membrane has a thickness of 0.2 to 0.5 mm, and a pore size of 3 to 15 μm.

[0016] The filtration device uses a three-layer structure of filter membrane-glass fiber-filter membrane, and each layer is designed with a specific thickness and pore size. Compared with the structural design of two-layer filter membranes, it solves the problem of residual whole blood samples causing filter membrane blockage or leakage, resulting in low plasma recovery rate and hemolysis, and increases the amount of plasma extracted.

[0017] Furthermore, the first and third blood filter membranes of the device are treated with a treatment solution containing a surfactant and dried at 37°C for 2 to 24 hours; the second glass fiber layer of the device is treated with an anti-RBC solution and dried at 37°C for 2 to 24 hours.

[0018] In some embodiments, the first and third blood filter membranes are treated with a surfactant treatment solution (used in an amount of 0.02 to 0.2 ml / cm2 ) for treatment, spray the treatment solution on the blood filter membrane. After adding the treatment solution, dry at 37°C for 2 to 24 hours or vacuum dry or freeze dry.

[0019] In some embodiments, the second layer of glass fiber is treated with a treatment liquid (the amount used is 0.03-0.1 ml / cm 2 ) for treatment, spraying the treatment liquid on the glass fiber. In addition, the treatment can also be carried out after loading into the filtration device, and after the treatment is completed, the top layer of blood filter membrane is loaded. After adding the treatment liquid, it is dried at 37°C for 2 to 24 hours or vacuum-dried or freeze-dried.

[0020] The surfactant treatment solution (blood filter membrane treatment solution) is a surfactant, PVP, etc. added to a buffer solution such as Tris-Hcl, PB (phosphate buffer), CB (carbonate buffer) or borate buffer. Among them, the surfactant is a non-ionic surfactant, such as S14 (Triton X-100), S19 (Tween 20), S20 (Tween 80) and S21 (Brij 35). The surfactant plays a key role in wet penetration in the process of whole blood and blood filter membrane combination, and will not damage red blood cells and cause red blood cell rupture. When the liquid can wet the solid, the combination of the two will be more firm, and the filtration speed will also be increased; PVP has the effects of solubilization, dispersion, adsorption, and film formation, and can increase some basically insoluble in water and active, can be adsorbed on many interfaces and reduce the interfacial surface tension to a certain extent. The toughness of the blood filter membrane after treatment increases, preventing the blood filter membrane from being damaged due to excessive solution or excessive pressure, increasing the speed of the solution passing through the blood filter membrane, and protecting the red blood cells from rupture.

[0021] The glass fiber treatment liquid is a buffer such as Tris-Hcl, PB (phosphate buffer), CB (carbonate buffer) or borate buffer, in which surfactants, protein stabilizers, chelating agents and biological substances (anti-RBC antibodies) are added. Among them, the anti-RBC antibody has a high affinity for red blood cells in the whole blood sample, can effectively fix or capture red blood cells in the whole blood without interfering with normal detection items, and effectively improves the accuracy of the test results; the protein stabilizer can specifically adsorb miscellaneous proteins (non-specific proteins), reduce non-specific binding of miscellaneous proteins, and eliminate false positives or false negatives.

[0022] In some methods, the treatment solution also includes a chelating agent and a preservative. The chelating agent is generally EDTA, EDTA-2Na, etc., which is a kind of chelating agent that can react with Mg 2+ , Ca 2+ , Mn 2+ , Fe 2+Chelating agents that bind to divalent metal ions such as calcium ions. Chelating agents can prevent blood coagulation. Chelating agents can chelate calcium ions in the blood and reduce the concentration of free calcium ions in the blood, thereby increasing the difficulty of prothrombin activation and effectively preventing blood from coagulating prematurely. This is crucial to ensure the accuracy and reliability of blood samples; at the same time, chelating agents can effectively inhibit the coagulation process, which can prolong the filtration time and provide operators with more operating space and time. Preservatives can also prevent blood coagulation and help keep blood samples in a liquid state for medical testing and analysis.

[0023] Furthermore, the filter device is directly nested above the reaction cup, so that the instrument can directly grab the filter device to separate the filter device from the reaction cup.

[0024] There are protruding platforms on the inner wall of the reaction cup and on the outer wall of the filter device, so the filter device will not fall after being placed in the reaction cup. The structure is firm, ensuring that the processing device will not fall or loosen due to pressure and other reasons, so that the whole blood can be initially filtered before being added to the reaction cup to remove unnecessary interfering substances, ensuring the safety and reliability of the entire filtering process. After filtering, the instrument automatically discards the filter device and draws the plasma in the reaction cup for testing, thereby avoiding the destruction of certain components in the blood during the centrifugal process and simplifying the complexity of whole blood processing.

[0025] In some methods, the top of the filter device is sealed by a soft rubber plug ring, so that the entire blood filtration and detection process is carried out in a closed reaction cup set, avoiding contamination of the blood sample by the external environment.

[0026] In some embodiments, a filter hole is provided at the bottom of the filter device, and the whole blood enters the reaction cup through the filter hole after being filtered through the filter membrane.

[0027] On the other hand, the present invention provides a method for pre-treating a whole blood sample using a whole blood pre-treatment device.

[0028] Furthermore, the method comprises the following steps:

[0029] (1) The filter device is directly mounted on the reaction cup to form a whole blood pretreatment device;

[0030] (2) adding whole blood into a whole blood pretreatment device;

[0031] (3) Pressurizing the whole blood pretreatment device, the whole blood is filtered by the filtration device and then permeates into the reaction cup.

[0032] (4) Add the tissue plasminogen activator-plasminogen activator inhibitor-1 complex assay kit (magnetic microparticle chemiluminescence method) detection reagent and use a chemiluminescence instrument to detect the plasma.

[0033] Furthermore, in the method, the whole blood sampling volume is 0.2-0.6 mL and the pressure is 5-15 kPa.

[0034] The whole blood pretreatment device provided by the present invention has different effects on the filtration of whole blood to separate plasma at different filtration pressures, filtration times and filtration volumes. Different filtration pressures and filtration times need to be set to filter different volumes of whole blood. Generally speaking, the filtration device in the present invention can filter a whole blood volume of 0.2 to 0.6 mL, and the requirement for the sample volume is relatively small, which can meet the need to quickly measure a small amount of samples.

[0035] In another aspect, the present invention provides a use of a membrane for preparing a filter membrane for a whole blood pretreatment device, wherein the first layer of the filter membrane is a blood filter membrane, the second layer is glass fiber, and the third layer is a blood filter membrane.

[0036] Furthermore, the first layer of blood filter membrane has a thickness of 0.2-0.5 mm, a pore size of 3-15 μm, and is made of a single-layer matrix membrane; the second layer of glass fiber has a thickness of 0.1-0.8 mm, a pore size of 0.1-0.3 mm, and is made of glass fiber; the third layer of blood filter membrane has a thickness of 0.2-0.5 mm, and a pore size of 3-15 μm.

[0037] On the other hand, the present invention provides a whole blood pretreatment device for preparing a plasma sample for chemiluminescence detection, wherein the whole blood pretreatment device comprises a package structure composed of a filtering device and a reaction cup.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] 1. Regarding the filter membrane setting in the filter device, a three-layer structure of blood filter membrane-glass fiber-blood filter membrane is adopted. The first and third layers use filter membranes of the same thickness and material. The first layer of blood filter membrane can effectively intercept most of the red blood cells, white blood cells and platelets, and the third layer can intercept the remaining red blood cells, white blood cells and platelets; the second layer of glass fiber material in the middle can effectively fix or capture the red blood cells in the whole blood without interfering with the normal detection items, effectively improving the accuracy of the test results, and providing a buffer for the red blood cells, increasing the liquid movement distance, and avoiding the rupture of red blood cells during the pressurization process.

[0040] 2. A pressure pump is used to control the air pressure in the filter device. Under the action of pressure, the whole blood passes through the filter device to separate blood cells from plasma. Different pressures are set according to the filtration volume of the whole blood sample to delay the occurrence of filter membrane blockage and avoid hemolysis of red blood cells to the greatest extent.

[0041] 3. It avoids the need to use centrifuges and other equipment for centrifugal treatment in traditional methods, reduces equipment costs, and saves time and effort. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 This is a vertical view of the whole blood pretreatment device in Example 1

[0043] Figure 2 The combination diagram of the filter device and the reaction cup in Example 1

[0044] Figure 3 The disassembled structure diagram of the filter device and the reaction cup in Example 1

[0045] Figure 4 A cross-sectional view of the filter device and the reaction cup in Example 1

[0046] Figure 5 The disassembled cross-sectional view of the filter device and the reaction cup in Example 1

[0047] Figure 6 This is a linear correlation analysis diagram of centrifugal treatment and filtration treatment in Example 5 DETAILED DESCRIPTION

[0048] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings. It should be noted that the embodiments described below are intended to facilitate the understanding of the present invention and do not have any limiting effect on it. The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0049] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

[0050] Embodiment 1: Whole blood pretreatment device provided by the present invention

[0051] The structure of the whole blood pretreatment device provided in this embodiment is as follows Figure 1-5 As shown, Figure 1 This is the elevation view of the whole blood pretreatment device. Figure 2 This is a diagram of the combination of the filtration device and the reaction cup. Figure 3 This is the split structure diagram of the filter device and the reaction cup. Figure 4 is a cross-sectional view of the filter device and the reaction cup. Figure 5 This is a cross-sectional view of the filter device and the reaction cup.

[0052] like Figures 1 to 3The whole blood pretreatment device 1 provided in this embodiment comprises a filter device 2, a reaction cup 3 and a pressure pump 4. The filter device 2 comprises a first layer of blood filter membrane 5 (purchased from whatman company, Fusion 5), an intermediate layer of glass fiber 6 (purchased from Shanghai Jieyi Biotechnology Co., Ltd., 8964) and a third layer of blood filter membrane 7 (purchased from whatman company, Fusion 5). The pressure pump 4 is connected to the top 9 of the filter device 2 through a conduit 15 connected to the outlet 8, and the top 9 and the conduit 15 are sealed and connected through an installed soft rubber plug ring 10. The filter device 2 is inserted into the reaction cup 3 through the outer wall protruding platform 16, and the bottom 11 is connected to the inner wall protruding platform 17 of the reaction cup 3.

[0053] Compared with the traditional whole blood filtering device, the whole blood pretreatment device 1 provided in this embodiment eliminates the need for centrifugal equipment, is easy to operate, and saves time and effort. After adding whole blood to the filtering device 2, a certain pressure value is increased by the pressure pump 4. After the blood is filtered through the first filter membrane 5, the middle layer of glass fiber 6 and the third filter membrane 7, the blood cells are blocked and remain in the filtering device 2, and the plasma flows through the three layers of filter membranes to the reaction cup below. The whole process is carried out in a closed environment, and the instrument discards the filtering device 2 in time after filtering, avoiding the contamination of the blood sample by the external environment and improving the accuracy of the test results.

[0054] like Figures 4-5 The filter device 2 is provided with a first layer of blood filter membrane 5, a middle layer of glass fiber 6 and a third layer of blood filter membrane 7, and the three layers are stacked in sequence. The outer shell of the filter device 2 is made of PP or PS material, the inner diameter of the bottom of the filter device is 5.6mm, the outer diameter is 6.75mm, and the length is 4cm. The aperture size of the filter hole 18 at the bottom 11 is 0.5-1.5mm, and the top 9 is sealed by the soft rubber plug ring 10 of the outlet 8 of the pressure pump 4. The soft rubber plug ring 10 is made of PTP material, which can not only play a buffering role, but also increase the sealing of the contact port.

[0055] Among them, the first layer of blood filter membrane has a thickness of 0.37mm, a pore size of 11μm, and is made of a single-layer matrix membrane; the second layer of glass fiber has a thickness of 0.1-0.8mm, a pore size of 0.2mm, and is made of glass fiber; the third layer of blood filter membrane has a thickness of 0.37mm, and a pore size of 11μm.

[0056] The design of the filter device 2 should be able to effectively filter the whole blood, retain the plasma, and avoid damaging the components in the plasma. The size of the reaction cup 3 is 6.79mm in inner diameter, 7.9mm in outer diameter, and 4cm in length. The whole blood filter device 2 is fixed on the reaction cup 3 by overlapping and embedding, so that a parallel and almost overlapping shape is formed between the filter device 2 and the reaction cup 3, so that the whole blood can be preliminarily filtered before being added to the reaction cup 3 to remove unnecessary substances such as red blood cells, white blood cells and platelets, while the plasma can flow down smoothly. In addition, the filter device 2 is discarded after the filtration is completed, and there is no need to clean it, which saves time and also avoids pollution caused by secondary use.

[0057] like Figure 1 The pressure pump 4 includes a pressure intensifier 12, a control valve 13, a display 14 and a conduit 15. The control valve 13 adjusts the pressure according to the current pressure value displayed by the display 14.

[0058] Before filtration, a surfactant treatment solution and an anti-RBC treatment solution are prepared, and the blood filter membrane 5 and the blood filter membrane 7 in the filtration device 2 are treated with the surfactant treatment solution, and the glass fiber 6 is treated with the anti-RBC treatment solution. 2 The surfactant treatment solution is sprayed on the blood filter membrane 5 and the blood filter membrane 7 at a concentration of 0.01-0.1 ml / cm 2 The anti-RBC treatment solution is sprayed on the glass fiber 6 at a concentration of , and then dried at 37°C for 2 to 24 hours or vacuum dried or freeze dried.

[0059] Then, the blood filter membrane and the treated glass fiber are cut into a circular shape (diameter 5.6 mm), and are placed into the filter device 2 in the order of the first layer of blood filter membrane 5, the middle layer of glass fiber 6, and the third layer of blood filter membrane 7. The filter device 2 is fixed on the reaction cup 3 by overlapping and embedding, so as to prepare the whole blood pretreatment device 1;

[0060] During the filtration process, the control valve 13 sets the delivery pressure value, and the air pressure generated by the booster 12 is transmitted to the filtration device 2 through the conduit 15, exerting a relatively constant pressure on the whole blood therein. Compared with the traditional method, the use of a pressure pump gets rid of the constraints of the centrifuge, does not require cumbersome centrifugation and supernatant removal steps, and also saves the time required for centrifugation, simplifying the steps of whole blood processing.

[0061] Example 2: Method for using the whole blood pretreatment device

[0062] The whole blood pretreatment device 1 provided in Example 1 is used to filter and detect whole blood. The specific operation method is as follows:

[0063] (1) Add the whole blood sample from the top 9 of the filter device 2 into the whole blood pretreatment device. After all the blood is added, the top 9 is sealed by the soft rubber stopper ring 10 of the pressure pump 4. In this embodiment, the volume of the whole blood is 0.5 ml;

[0064] (2) Control valve 13 to set a pressure value and open the valve. In this embodiment, the pressure value is set to 10 KPa and lasts for 10 seconds. Under the pressure, the whole blood sample is filtered through the first layer of blood filter membrane 5, the middle layer of glass fiber 6, and the third layer of blood filter membrane 7 and then penetrates into the reaction cup. At this time, the filter device is discarded.

[0065] (3) Add tPAI.C detection reagent (tissue plasminogen activator-plasminogen activator inhibitor-1 complex assay kit (magnetic microparticle chemiluminescence method)) to reaction cup 3, and detect plasma using a chemiluminescence instrument.

[0066] Example 3: The present invention provides a surface active treatment solution preparation

[0067] Weigh 0.01-0.1M Tris buffer / 0.01-0.2M PB buffer / 0.01-0.1M CB buffer / 0.01-0.1M boric acid buffer, 0.01-2% BSA or Casein, 0.1-2% surfactant, 0.01-0.5% preservative, 0.1-2% PVP, and 0.01-1% chelating agent in a mass ratio of (1L:10g:1mL:1mL:5g:1g), mix well, and set aside.

[0068] Example 4: Preparation of the anti-RBC treatment solution provided by the present invention

[0069] Weigh 0.01-0.1M Tris buffer / 0.01-0.2M PB buffer / 0.01-0.1M CB buffer / 0.01-0.1M boric acid buffer, 0.01-2% BSA or Casein, 0.1-2% surfactant, 0.01-0.5% preservative, 0.1-2% PVP, 0.01-1% chelating agent, and 0.001mg / mL-1mg / mL anti-RBC according to the mass ratio of (1L:10g:1mL:1mL:5g:1g:100mg), mix well and set aside.

[0070] Anti-RBC antibodies have a high affinity for red blood cells in whole blood samples and can effectively fix or capture red blood cells in whole blood without interfering with normal test items, effectively improving the accuracy of test results.

[0071] Example 5: Preparation of filter membranes of the size provided by the present invention

[0072] The three-layer filter membrane is as follows: the first layer of blood filter membrane has a thickness of 0.37mm, a pore size of 11μm, and is made of a single-layer matrix membrane; the second layer of glass fiber has a thickness of 0.1-0.8mm, a pore size of 0.2mm, and is made of glass fiber; the third layer of blood filter membrane has a thickness of 0.37mm, a pore size of 11μm, and is cut into 0.246cm 2 Circular filter disc.

[0073] Example 6: Selection of filter membranes of different materials

[0074] A sample pad commonly used in the laboratory was selected and cut according to the area in Implementation Case 5, and installed in the filtration device for whole blood filtration test, wherein the whole blood filtration volume was 0.5 ml, the filtration pressure was 10 kPa, and the filtration time was 10 s. The test results are shown in Table 1.

[0075] Table 1 Screening test of different materials

[0076]

[0077] It can be seen that all three materials have hemolysis after filtering whole blood, but the plasma state after filtration by glass fiber and blood filter membrane is better than that by polyester fiber membrane. The reason for hemolysis may be that the amount of plasma is large and the overall thickness of the glass fiber filter membrane pad is not enough, resulting in leakage, hemolysis or blockage of red blood cells.

[0078] Example 7: Screening of different filtration membrane combinations

[0079] The filter membranes in Example 5 were installed in the filtration device according to the 8 combinations in Table 2 to perform whole blood filtration tests. The whole blood filtration volume was 0.5 ml, the filtration pressure was 10 kPa, and the filtration time was 10 s. The comparative screening results are shown in Table 2.

[0080] Table 2 Screening test of different filtration membrane combinations

[0081]

[0082]

[0083] Combined with Table 2, it can be seen that compared with filtering with only two filter membranes, the combined structure of blood filter membrane-glass fiber-blood filter membrane recovers a normal amount of plasma, and the plasma state and plasma color meet the requirements, and there is no hemolysis. The reason may be that the combined mode can effectively reduce the leakage or blockage of red blood cells.

[0084] Example 8: Assembly of whole blood pretreatment device

[0085] The blood filter membrane and the treated glass fiber are cut into circles and placed into the filtration device in the order of the first layer of blood filter membrane, the middle layer of glass fiber and the third layer of blood filter membrane. The filtration device 2 is fixed on the reaction cup 3 by overlapping and embedding to make a whole blood pretreatment device.

[0086] Example 9: Verification of surfactant treatment solution

[0087] The treatment liquids in Examples 3-4 were used to treat the first and third layers of blood filter membranes in Example 5, and the glass fibers were treated with the treatment liquid in Example 4. The control group was the first and third layers of blood filter membranes in Example 5 without treatment. Afterwards, the filtration devices were prepared according to the filtration membranes provided in Example 8 to perform whole blood filtration tests, wherein the whole blood filtration volume was 0.5 ml, the filtration pressure was 10 kPa, and the filtration time was 5-20 s. The test results are shown in Table 3.

[0088] Table 3 Surfactant treatment liquid verification

[0089]

[0090]

[0091] From the results in Table 3, it can be seen that the filtration speed of the blood filter pad treated with a surfactant is faster than that of the untreated one. The reason is that the toughness of the treated blood filter membrane is increased, which prevents the blood filter membrane from being damaged due to excessive solution or excessive pressure, increases the speed at which the solution passes through the blood filter membrane, and protects the red blood cells from rupture; it is faster than the treatment containing anti-RBC treatment solution. The reason is that the pore size of the first layer of blood filter membrane is small, and after treatment with the anti-RBC treatment solution, the adsorbed red blood cells increase, causing the blood filter membrane to be blocked, and the whole blood cannot be completely filtered.

[0092] Example 10: Validation of anti-RBC treatment solution

[0093] The treatment solutions in Examples 3 to 4 were used for treating the glass fibers in Example 5, respectively. Meanwhile, the first and third layers of the blood filter membrane were treated with the treatment solution in Example 3. The control group was the glass fibers in Example 5 that were not treated with the treatment solution. Then, a filtration device was prepared according to the filtration membrane provided in Example 8 to perform a whole blood filtration test. The whole blood filtration volume was 0.5 ml, the filtration pressure was 10 kPa, and the filtration time was 5 to 20 s. The test results are shown in Table 4.

[0094] Table 4 Anti-RBC treatment fluid validation test

[0095]

[0096] From the results in Table 4, it can be seen that after the glass fiber is treated with a treatment solution containing anti-RBC antibodies, compared with the two groups of tests treated with a surfactant treatment solution (without anti-RBC antibodies) and the second layer without treatment solution, the plasma can be completely filtered out and no hemolysis will occur. The reason may be that anti-RBC can fix a part of the red blood cells and reduce the filtration pressure of the third layer, indicating that the glass fiber can only be treated with a treatment solution containing anti-RBC antibodies.

[0097] Example 11: Verification of whole blood filtration volume, filtration pressure and filtration time

[0098] In order to further illustrate the beneficial effects of the filtration pressure, filtration time and filtration volume of the whole blood pretreatment device provided by the present invention on improving the filtration of whole blood plasma separation, relevant verification experiments were carried out.

[0099] (I) Filtration volume verification

[0100] Table 5 Whole blood filtration volume screening

[0101]

[0102] It can be seen from Table 5 that, under the condition of constant filtration time and filtration pressure, when the whole blood volume is less than 0.7 ml, the plasma can be completely filtered out; when it exceeds 0.7 ml, the red blood cells rupture and the plasma hemolyzes, so 0.2 to 0.6 ml of whole blood can be filtered.

[0103] (II) Filtration pressure verification

[0104] Table 6 Whole blood filtration pressure screening

[0105]

[0106] It can be seen from Table 6 that, when the filtration volume and filtration time are constant, if the pressure is less than 5 kPa, the plasma cannot be completely filtered out, and if it exceeds 15 kPa, the red blood cells will rupture and the plasma will hemolyze. Therefore, the appropriate pressure is 5-15 kPa.

[0107] (III) Filtering time verification

[0108] Table 7 Whole blood filtration time screening

[0109]

[0110] It can be seen from Table 7 that when the filtration volume and filtration pressure are constant, the best pressure duration is 5S to 15S.

[0111] Example 12: Comparison of whole blood centrifugation and filtration

[0112] In order to further illustrate that the filtering effect of the whole blood treatment device in the present invention is consistent with the centrifugal treatment effect, 30 whole blood samples were selected for further relevant comparative experiments. The data are shown in Table 8 and Figure 1 As shown. The target of chemiluminescence detection is tissue plasminogen activator-plasminogen activator inhibitor-1 complex (tPAI.C), the sample is a whole blood sample, and the detection method is to prepare 30 whole blood samples, each sample is divided into 2 parts, each 0.5mL, centrifuged by a centrifuge and filtered by a whole blood filter device, and the amount of plasma obtained is measured, and the plasma is tested on the machine to calculate the linear correlation coefficient of the two sets of data.

[0113] Table 8 Filtration effects of different samples treated in two ways

[0114]

[0115]

[0116] The above results show that there is no difference in the results of whole blood filtration using a filtration device and centrifugation.

[0117] The above is only a specific implementation of the present invention, but the design concept of the present invention is not limited thereto. Any non-substantial changes to the present invention using this concept shall be deemed as an infringement of the protection scope of the present invention.

Claims

1. A whole blood pretreatment device, It is characterized in that The invention comprises a set structure composed of a filter device and a reaction cup. The filter device comprises a layer of blood filter membrane, a layer of glass fiber and a layer of blood filter membrane from top to bottom.

2. The device according to claim 1, It is characterized in that Also included is a pressure pump, which applies pressure to the filtering device.

3. The device according to claim 1, It is characterized in that The first and third layers have the same material and thickness, and the second layer has a larger aperture than the first layer.

4. The device as claimed in claim 3, It is characterized in that The first layer of blood filter membrane has a thickness of 0.2-0.5 mm and a pore size of 3-15 μm, and is made of a single-layer matrix membrane; the second layer of glass fiber has a thickness of 0.1-0.8 mm and a pore size of 0.1-0.3 mm, and is made of glass fiber; the third layer of blood filter membrane has a thickness of 0.2-0.5 mm and a pore size of 3-15 μm.

5. The device according to claim 1, It is characterized in that The first and third layers of blood filter membranes are treated with a treatment solution containing a surfactant, and the second layer of glass fiber is treated with an anti-RBC solution.

6. A whole blood pretreatment method, It is characterized in that A whole blood sample is pretreated using the whole blood pretreatment device as described in any one of claims 1 to 5.

7. The method according to claim 6, It is characterized in that The following steps are involved: (1) The filter device is directly mounted on the reaction cup to form a whole blood pretreatment device; (2) adding whole blood into a whole blood pretreatment device; (3) Pressurizing the whole blood pretreatment device, the whole blood is filtered by the filtration device and then permeates into the reaction cup. (4) Add the tissue plasminogen activator-plasminogen activator inhibitor-1 complex assay kit (magnetic particle chemiluminescence method) detection reagent and use a chemiluminescence instrument to detect the plasma.

8. The whole blood filtration method according to claim 7, It is characterized in that The whole blood sampling volume is 0.2-0.6 mL, and the pressure is 5-15 kPa.

9. Use of a membrane for preparing a filter membrane for a whole blood pretreatment device, It is characterized in that The first layer of the filter membrane is a blood filter membrane, the second layer is glass fiber, and the third layer is a blood filter membrane.

10. Use of the whole blood pretreatment device according to any one of claims 1 to 5 for preparing plasma samples for chemiluminescence detection, comprising a package structure composed of a filter device and a reaction cup.

Citation Information

Patent Citations

  • Method for obtaining plasma from whole blood sample, blood filter and micro-fluidic chip

    CN110857904A

  • Combined filter and device for separating plasma from whole blood and method for separating plasma from whole blood

    CN117180991A